The medicine opens the door. The therapy is what walks through it.
Ketamine-Assisted Psychotherapy (KAP) is not a ketamine infusion. It is not a prescription you take at home. It is psychotherapy — deep, structured, relationally grounded psychotherapy — that uses ketamine to create conditions where therapeutic work can reach places it otherwise cannot.
The distinction matters enormously, and the confusion between these different delivery models is one of the most significant obstacles to understanding what KAP offers and who it helps.
Ketamine is a dissociative anesthetic that, at subanesthetic doses, produces two effects of particular relevance to psychotherapy.
Neuroplasticity: Ketamine promotes the rapid growth of new synaptic connections in the brain, particularly in the prefrontal cortex and hippocampus — regions critical for emotional regulation, memory processing, and executive function. This effect, mediated primarily through BDNF (brain-derived neurotrophic factor) and mTOR signaling pathways, creates what clinicians describe as a window of neuroplasticity: a period of heightened capacity for the brain to form new connections, new patterns, and new ways of organizing experience. This window lasts approximately 24–72 hours following a dose, and it is during this window that the therapeutic work has its greatest potential impact.
Default Mode Network (DMN) Modulation: Ketamine temporarily reduces activity in the brain’s default mode network — the neural circuitry associated with self-referential thinking, rumination, and the maintenance of habitual patterns of thought and identity. When DMN activity is reduced, rigid patterns loosen. The client can access material, perspectives, and emotional states that are normally defended against or simply unavailable. Entrenched narratives (“I am broken,” “Nothing will ever change,” “I am unlovable”) temporarily lose their grip, creating space for the therapeutic work to introduce new relational and emotional experiences that would be blocked under ordinary conditions.
Ketamine does not do the healing. It creates the conditions under which healing becomes possible. The therapy does the rest.
Not all ketamine treatment is the same. The delivery model determines the clinical outcome, and the differences are not trivial.
IV ketamine infusion clinics administer ketamine intravenously, typically at higher doses, over a series of sessions. The patient sits in a recliner, often with an eye mask, and the ketamine is delivered through an IV while medical staff monitor vital signs. There is typically no psychotherapist present and no structured therapeutic process surrounding the infusions.
The infusion model can produce rapid improvement in mood, particularly for treatment-resistant depression. The neuroplasticity effects are real, and many patients report significant acute relief. However, research consistently shows that the effects of ketamine infusions alone tend to be temporary — typically lasting days to weeks before symptoms return. Without a therapeutic framework to help the brain use the neuroplastic window to build new patterns, the window opens and closes without lasting structural change. The patient may need repeated infusions indefinitely, at significant cost, without achieving durable resolution.
Some providers prescribe sublingual or intranasal ketamine for home use, sometimes with a brief telehealth check-in before or after. While this model increases access and reduces cost, it lacks both the medical monitoring of an infusion setting and the therapeutic depth of a KAP model. The patient is alone during the experience — without the relational container, the clinical expertise, and the structured integration that make the difference between a temporary chemical experience and a transformative therapeutic process.
In the therapist-led model, ketamine is one component of a comprehensive psychotherapeutic treatment. The therapist and client prepare extensively before the first dose: building the therapeutic relationship, identifying treatment targets, developing grounding skills, and setting intentions for the work. A prescribing clinician conducts a separate medical evaluation, reviews the medication regimen, and authorizes the dosing protocol.
During dose sessions, the client takes a sublingual rapid-dissolving tablet in the therapist’s office. The therapist is present throughout the experience — not as a passive monitor but as an active therapeutic partner. The experience lasts five to seventy-five minutes depending on the dose. During this time, the therapist works with whatever emerges: memories, emotions, somatic experiences, relational material, parts of self. The reduced DMN activity and heightened neuroplasticity create conditions where deeply defended material becomes accessible, and the therapeutic relationship provides the safety needed to work with that material productively.
Integration sessions follow every dose session. This is where the material that emerged is processed, contextualized, connected to the broader treatment arc, and translated into lasting change. The neuroplastic window is deliberately used: integration work during this period has heightened impact because the brain is in an enhanced state of receptivity to new learning.
The difference between ketamine treatment and ketamine-assisted psychotherapy is the difference between opening a door and walking through it into a new room.
KAP is not appropriate for everyone, and it is not a first-line treatment for most presentations. It is best understood as a tool for cases where standard approaches have reached their limits — or where the client’s defenses are so entrenched that therapeutic material cannot be accessed through conventional means.
Strong candidates for KAP typically include: individuals with treatment-resistant depression who have not responded to medication and talk therapy; complex trauma survivors whose defensive structures prevent access to core material; clients with deeply entrenched negative self-beliefs that resist cognitive restructuring; individuals experiencing existential distress, spiritual crisis, or end-of-life anxiety; and clients who have been in therapy for extended periods without reaching the material that maintains their suffering.
KAP may not be appropriate for individuals with active psychosis, certain seizure disorders, uncontrolled hypertension, active substance use disorders involving ketamine or other dissociatives, or those who are not currently engaged in ongoing psychotherapy. Medical screening by the prescribing clinician determines eligibility.
KAP at Samadhi Healing Collective follows the therapist-led model described above. I am the treating psychotherapist throughout — from the initial assessment through preparation, dose sessions, and integration. The prescribing clinician provides medical oversight through Journey Clinical. The therapeutic framework integrates EMDR, Internal Family Systems, and somatic approaches with the ketamine experience, tailored to each client’s presentation and treatment goals.
This is not a standardized protocol applied uniformly. Each client’s KAP treatment is built from their specific history, their attachment patterns, their nervous system state, and their therapeutic goals. The ketamine serves the therapy. The therapy serves the client.
Ketamine therapy typically refers to medical administration of ketamine — often IV infusions — for symptom relief, with limited or no psychotherapy during the session. Ketamine-assisted psychotherapy (KAP) is different: a trained therapist is present throughout the experience, guiding you through the psychological material that emerges. In KAP, the medicine is a tool that supports the therapy. The therapy is the treatment.
Spravato is a nasal spray containing esketamine, one half of the ketamine molecule. It is FDA-approved for treatment-resistant depression and administered in a clinical setting with monitoring but typically without psychotherapy during the session. KAP uses racemic ketamine — the full molecule — at doses that support a therapeutic journey, with a therapist actively guiding the process. The depth of the psychological experience and the presence of a therapist throughout are the primary distinctions.
A typical course of KAP at our practice includes two to four preparation sessions, three to six dosing sessions (each followed by an integration session), and ongoing integration as needed. The total number varies based on what you’re working through and how you respond. KAP is not designed to be indefinite — the goal is deep, durable change, not ongoing maintenance.
The preparation and integration therapy sessions are often covered by insurance, as they are standard psychotherapy. The ketamine dosing sessions themselves are not currently covered by most insurance plans and are paid out of pocket. We accept HSA and FSA funds for the dosing sessions. We’re happy to discuss costs and options during a consultation.
Ketamine has been used safely in medical settings for over fifty years. At the doses used in KAP, it has a wide safety margin and is well-tolerated by most people. Medical clearance is required before beginning treatment, and a prescribing physician oversees the medical aspects of care. Your therapist is present throughout every dosing session. KAP is not appropriate for everyone — certain medical and psychiatric conditions are contraindicated — and a thorough screening process ensures it is a good fit before treatment begins.
If something on this page resonated, reach out to schedule a consultation.